Roanna Ruiz
Stock Analyst at Leerink Partners
(0.85)
# 4,009
Out of 5,152 analysts
60
Total ratings
32.5%
Success rate
-13.19%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $83 → $84 | $62.19 | +35.07% | 2 | Feb 26, 2026 | |
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $2.64 | -24.24% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.04 | +49.01% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.19 | +488.24% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $6.30 | +185.71% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.64 | -39.02% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $9.10 | +119.78% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $9.12 | +196.05% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.26 | +205.16% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.27 | +123.29% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $330 | $485.06 | -31.97% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $34.04 | -26.56% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.74 | +256.62% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $5.30 | +13.21% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $30.14 | -36.96% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $76.31 | +57.25% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $6.66 | +650.75% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $14.18 | +182.09% | 6 | Oct 19, 2022 |
Cytokinetics
Feb 26, 2026
Maintains: Outperform
Price Target: $83 → $84
Current: $62.19
Upside: +35.07%
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $2.64
Upside: -24.24%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.04
Upside: +49.01%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.19
Upside: +488.24%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $6.30
Upside: +185.71%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.64
Upside: -39.02%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $9.10
Upside: +119.78%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.12
Upside: +196.05%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.26
Upside: +205.16%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.27
Upside: +123.29%
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $485.06
Upside: -31.97%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $34.04
Upside: -26.56%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.74
Upside: +256.62%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $5.30
Upside: +13.21%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $30.14
Upside: -36.96%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $76.31
Upside: +57.25%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $6.66
Upside: +650.75%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $14.18
Upside: +182.09%